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Summary
 
Proteins subject to proteolysis or phosphorylation during apoptosis are commonly precipitated
by autoantibodies found in the serum of patients with systemic lupus erythematosus (SLE). We
screened a panel of murine monoclonal and human monospecific sera reactive with known au-
toantigens for their ability to selectively precipitate phosphoproteins from apoptotic Jurkat T
cell lysates. Sera known to recognize the U1–small nuclear ribonucleoprotein (snRNP) com-
plex (confirmed by their ability to precipitate U1–snRNA) selectively precipitated a phospho-
protein complex (pp54, pp42, pp34, and pp23) from apoptotic lysates. Monoclonal antibodies
reactive with U1–snRNP proteins precipitated the same phosphoprotein complex from apop-
totic lysates. The phosphorylation and/or recruitment of these proteins to the U1–snRNP
complex is induced by multiple apoptotic stimuli (e.g., Fas ligation, gamma irradiation, or UV
irradiation), and is blocked by overexpression of bcl-2. The U1–snRNP-associated phosphoprotein
complex is immunoprecipitated by monoclonal antibodies reactive with serine/arginine (SR)
proteins that comprise a structurally related family of splicing factors. The association of phos-
phorylated SR proteins with the U1–snRNP complex in cells undergoing apoptosis suggests a
mechanism for regulation of alternative splicing of apoptotic effector molecules.
 
C
 
omponents of ribonucleoproteins (RNPs)
 
1
 
 such as
Ro, La, heterogeneous nuclear (hnRNP), and small
nuclear (snRNP) are commonly recognized by autoanti-
bodies found in the serum of patients with autoimmune
disease (1–4). The mechanisms by which these and other
autoantigens escape tolerance are largely unknown. The ob-
servation that keratinocytes subjected to ultraviolet radia-
tion express autoantigens such as Ro, La, and the U1-70 kD
snRNP protein at cell surface blebs suggests that apoptotic
cells may play an important role in the production of au-
toantibodies (5–7). This is supported by experiments dem-
onstrating the development of autoantibodies after immu-
nization of mice with apoptotic cells (8). Proteolytic
cleavage of at least 13 known protein autoantigens by indi-
vidual interleukin-1
 
b
 
 converting enzyme (ICE) family pro-
teases (now collectively termed cysteine protease with as-
partic acid substrate specificity, or “caspases” [9]) during
programmed cell death further supports this hypothesis. To
date, over half of all caspase targets are autoantigens or are
constituents of larger complexes that contain a protein that
is cleaved, and include the U1-70 kD snRNP (10), poly A
ribose polymerase (PARP; reference 11), DNA-dependent
protein kinase (DNA-PK; 12), hnRNP C1 and C2 (13),
lamins A, B, and C (14), the nuclear mitotic apparatus pro-
tein (NuMA; 15, 16), topoisomerases 1 and 2 (16), the nu-
cleolar protein UBF/NOR-90 (16), and 
 
a
 
 fodrin (17, 18).
Although proteolysis could expose novel epitopes re-
quired for the production of autoantibodies, only a fraction
of the known autoantigens are cleaved during apoptosis.
Recently, we reported that phosphoproteins are commonly
 
1
 
Abbreviations used in this paper: 
 
DNA-PK, DNA-dependent protein ki-
nase; HI-FCS, heat-inactivated FCS; hnRNP, heterogeneous nuclear RNP;
MCTD, mixed connective tissue disease; NuMA, nuclear mitotic appara-
tus protein; PARP, poly A ribose polymerase; PCNA, proliferating cell
nuclear antigen; PVDF, polyvinylidene difluoride; RNP, ribonucleopro-
tein; snRNP, small nuclear RNP; SLE, systemic lupus erythematosus; Sm,
Smith complex; SR, serine/arginine; SRP, signal recognition particle;
TIAR, T cell intracellular antigen-related protein.
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precipitated from apoptotic cell extracts by autoantibodies
derived from patients with systemic lupus erythematosus
(SLE), suggesting that protein modifications accompanying
apoptosis might generally predispose to autoantibody for-
mation (19). We previously identified seven phosphopro-
teins (termed pp200, pp54, pp46, pp42, pp34, pp23, and
pp17) in Jurkat T cells that are specifically precipitated with
autoimmune sera in response to apoptotic stimuli (19). We
also showed that a serine kinase activity is present in immu-
noprecipitates prepared from apoptotic Jurkat cell extracts
using sera from patients with SLE and SLE overlap syn-
dromes. We proposed that phosphorylation of autoantigens
may be a common sequela of apoptotic cell death, and we
postulated that these phosphoproteins, like other kinase
substrates, such as c-jun, may be involved in the effector
arm of the cell death pathway.
Well-characterized, monospecific human sera have been
used in several recent studies to identify autoantigens that
are cleaved during apoptosis (12, 16). We have used a simi-
lar approach to identify autoantigens that are selectively
phosphorylated during apoptosis. Although most of the sera
did not precipitate phosphoproteins from radiolabeled apop-
totic lysates, five sera known to recognize the U1–snRNP
complex precipitated phosphoproteins migrating with ap-
parent molecular masses of 54, 42, 34, and 23 kD by SDS-
PAGE. A series of human autoimmune sera directed against
the U1–snRNP, but not the U2–snRNP, also coprecipi-
tated this same phosphoprotein complex. Identical results
were obtained using anti-U1A human variable domain an-
tibody fragments and monoclonal antibodies directed against
individual components of U–snRNPs. Because the relative
migration of these U1–snRNP-associated phosphoproteins
resembled the serine/arginine (SR) complex of splicing fac-
tors, we used antibodies reactive with SR proteins to pre-
cipitate phosphoproteins from apoptotic lysates. A mono-
clonal antibody specific for a phosphoepitope common to
all SR proteins (mAb104) and a monoclonal antibody spe-
cific for the phosphorylated form of the SR protein SC35
precipitated a similar phosphoprotein complex from these
lysates. The identification of SR proteins as potential sub-
strates for a serine kinase that is activated during apoptosis has
important implications for understanding cell death path-
ways, RNA splicing, and the immune response in diseases
that are characterized by the development of autoantibodies.
 
Materials and Methods
 
Cell Culture.
 
Jurkat cells were grown in 5% CO
 
2
 
 at 37
 
8
 
C us-
ing RPMI 1640 (BioWhittaker, Inc., Walkersville, MD) supple-
mented with 9% heat-inactivated FCS (HI-FCS; Tissue Culture
Biologicals, Tulare, CA), penicillin, and streptomycin (Media-
tech, Inc., Herndon, VA). Cells were grown and harvested at mid-
log phase. Jurkat T cells engineered to stably overexpress bcl-2
(or empty vector), a gift from John Reed (the La Jolla Cancer
Research Foundation, La Jolla, CA), were grown in RPMI me-
dium as described above supplemented with G418 (GIBCO
BRL, Gaithersburg, MD) at a final concentration of 500 
 
m
 
g/ml.
Protein overexpression was confirmed by Western blotting.
 
Metabolic Labeling.
 
Labeling was performed as described (19).
In brief, Jurkat cells were incubated at a density of 2 
 
3
 
 10
 
6
 
 cells/
ml in labeling medium containing the following: 45% RPMI
1640, 45% RPMI 1640 lacking either phosphate (GIBCO BRL)
or methionine and cysteine (GIBCO BRL), 2 mM glutamine
(Mediatech, Inc.), 5% HI-FCS, and 5% HI-FCS that had been
dialyzed to equilibrium against a buffer containing 10 mM Hepes
and 140 mM NaCl (Sigma Chemical Co., St. Louis, MO).
[
 
32
 
P]orthophosphate or [
 
35
 
S]methionine and cysteine (Dupont-
NEN, Boston, MA) was added at a concentration of 0.1 mCi/ml.
Cells were incubated at 37
 
8
 
C for 10–16 h to allow the cells to
reach steady state before each treatment, unless otherwise indi-
cated. For two-dimensional tryptic phosphopeptide mapping ex-
periments, cells were labeled for 2 h, followed by a 3-h stimula-
tion with anti-Fas antibodies (7C11) in labeling media composed
of 90% RPMI 1640 lacking phosphate, 2 mM glutamine, 10% di-
alyzed HI-FCS, and 0.15 mCi/ml 
 
32
 
P-orthophosphate.
 
Cell Lysis.
 
Lysis of cells was performed using NP-40 (Sigma
Chemical Co.) lysis buffer (1% NP-40, 150 mM NaCl, 50 mM
Tris, pH 7.8, and 1 mM EDTA). NP-40 lysis buffer was supple-
mented immediately before use with 1 mM sodium vanadate
(Sigma Chemical Co.) and a 100
 
3
 
 protease inhibitor cocktail pre-
pared by dissolving 10 mg chymostatin, 1.5 mg leupeptin, 7 mg
pepstatin A, 850 mg phenylmethylsulfonyl fluoride, 500 mg benz-
amidine, and 5 mg aprotonin in 50 ml of ethanol by stirring over-
night (20). The solution was sterilized by filtration and stored at
room temperature. All chemicals were purchased from Sigma
Chemical Co. After addition of 1 ml lysis buffer, the lysate was
incubated on ice for 30 min, centrifuged in a refrigerated mi-
crofuge (5402; Eppendorf Inc., Hamburg, Germany) at 14,000
rpm for 15 min, and then the supernatant was used immediately
for each experiment.
 
UV Irradiation.
 
Labeled Jurkat cells were plated on 100 
 
3
 
 15-mm
polystyrene petri dishes (Nunc, Thousand Oaks, CA) at a con-
centration of 2 
 
3
 
 10
 
6
 
 cells/ml and irradiated in a Stratalinker
2400 (Stratagene, La Jolla, CA) at a distance of 9 cm for 18 s. Af-
ter irradiation, cells were incubated at 37
 
8
 
C for the indicated
times before harvesting.
 
Gamma Irradiation.
 
Labeled cells were placed in a 50-ml con-
ical tube and irradiated at a dose of 3,300 rad from a Cesium 137
source using an irradiator (Gammacell 1000; Nordion Interna-
tional, Kanata, Ontario, Canada). After irradiation, cells were placed
in culture dishes at 37
 
8
 
C and incubated for the indicated times
before harvesting.
 
Cellular Activation.
 
Labeled Jurkat cells were treated with the
following antibodies: anti-Fas antibody 7C11 (provided by Mich-
ael Robertson, Indiana University, Bloomington, IN) from hy-
bridoma supernatant at a final dilution of 1:500; and anti-CD3
antibody (Coulter Immunology, Hialeah, FL) at a concentration
of 5 
 
m
 
g/ml followed by goat anti–mouse antibody (Jackson Im-
munoResearch Laboratories, West Grove, PA) at the same con-
centration. Cells were incubated at 37
 
8
 
C for the indicated times
before harvesting.
 
Immunoprecipitation and Western Blot Analysis.
 
Lysates were pre-
cleared  once with 25 
 
m
 
l of a 50% solution of protein A–Sepharose
(Pharmacia, Uppsala, Sweden) in PBS and 5 
 
m
 
g rabbit anti–mouse
(RAM) IgG (Jackson ImmunoResearch Laboratories) for 1 h, fol-
lowed by two preclears with protein A–Sepharose overnight.
Mouse monoclonal antibodies (5 
 
m
 
g) and 5 
 
m
 
g RAM (IgG or
IgM), or 2 
 
m
 
l patient serum alone were used in precipitation ex-
periments. Immunoprecipitation experiments using anti-U1A hu-
man antibody fragments were performed as described (21). The fol-
lowing human polyclonal antibodies were stored at 
 
2
 
70
 
8
 
C until 
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used: anti-Ro, anti-La, anti–Smith complex (Sm), anti–Jo-1, anti-
nucleolar, anticentromere, anti–Scl-70, anti-DNA, and anti-U1–
RNP (Arthritis Foundation/CDC Reference Sera, Atlanta, GA);
anti-Th/To, anti–U3-fibrillarin, anti-signal recognition particle
(SRP), anti–PL-7, and anti–PL-12 (T. Medsger and N. Fertig,
University of Pittsburgh School of Medicine, Pittsburgh, PA); two
different anti-U1/U2 monospecific sera (Sera Ya and Ga; refer-
ence 22) and anti-SRP (J. Craft, Yale University School of Med-
icine, New Haven, CT); anti-NuMA (serum AS), and anti-UBF
(serum JO; E. Tan and C. Casiano, The Scripps Institute, La Jolla,
CA); anti–RNA polymerase I/III and II (serum KA), anti–poly-
merase I/III (serum IM), anti-Th/To, anti–U3-fibrillarin, anti-
Ku, and anti–Scl-70 (M. Kuwana, Keio University Medical
School, Tokyo, Japan); anti-ribosomal
 
 P 
 
and antihistone/U–
RNP (Immunovision Inc., Springdale, AZ); anti–U1-70 kD sn-
RNP protein (A. Rosen, the Johns Hopkins University School of
Medicine, Baltimore, MD); anti-sp140, and anti-sp100 (D.
Bloch, Massachusetts General Hospital, Boston, MA); seven hu-
man sera specific for the U1–snRNP complex (B83, B152, B175,
H34, H165, K4, and L41) and a control serum specific for both
U1 and U2–snRNPs (V26) have been reported previously (23,
91). Serum from patients with SLE and mixed connective tissue
disease (MCTD) with high titers of antibodies against Sm and
RNP components, respectively, were provided by P.H. Schur
(Brigham and Women’s Hospital, Boston, MA). Autoimmune
serum capable of precipitating pp54, pp42, pp34, and pp23 (cor-
responding to patients 1, 8, 11, and 12) were described previously
(19). Serum from a fifth patient (patient 3) also coprecipitated
these proteins but was unavailable in sufficient quantity to com-
plete the studies described below (19). The following mouse
monoclonal antisera were stored at 
 
2
 
70
 
8
 
C until used: anti-lamin
B (E3), and anti–lamin A
 
1
 
B (E6; E.A. Nigg, University of Ge-
neva, Geneva, Switzerland); anti–lamin B (Calbiochem-Nova-
biochem Corp., San Diego, CA); anti–proliferating cell nuclear
antigen (PCNA; Zymed Laboratories, Inc., South San Francisco,
CA); anti–DNA-PK (D. Weaver, Dana Farber Cancer Institute,
Boston, MA); two monoclonal anti-Ku antibodies (C. Zhang,
Dana Farber Cancer Institute, Boston, MA); anti-Ki67 (D. Bloch,
Massachusetts General Hospital, Boston, MA); anti–U1-70 kD (ref-
erence 24; S. Hoch, the Agouron Institute, La Jolla, CA); anti-Sm
Y12 (J. Craft, Yale University School of Medicine, New Haven,
CT); anti-U1A/U2B
 
99
 
 9A9 (25); anti-U2B
 
99
 
 4G3 (25); anti-Ro60
2G10 (26); anti-Ro52 and anti-La SW5 (27) have been described
previously; mAb104 monoclonal directed against SR proteins
(reference 28; R. Reed, Harvard University School of Medicine,
Boston, MA); anti-SC35 (Sigma Chemical Co.); and antifibril-
larin monoclonal antibodies (72B9.D31 and 17C12.G9) and two
monoclonal antibodies directed against other U3–snRNP com-
ponents (7G3.B7 and 6G10.D3; K.M. Pollard, Scripps Institute,
La Jolla, CA). Serum from healthy control patients was a gift from
P. Fraser (Brigham and Women’s Hospital, Boston, MA). Immu-
noprecipitations were performed after addition of 1% BSA (Inter-
gen Company, Purchase, NY) in PBS to a total volume of 500 
 
m
 
l
and rotation in a 4
 
8
 
C cold room for 2–24 h. Comparison of pre-
cipitates showed no difference between incubation times for peri-
ods of up to 72 h. Precipitates were harvested by centrifuging
for 15 s at 14,000 rpm in a refrigerated Eppendorf microfuge,
washing three times with NP-40 lysis buffer supplemented with
protease inhibitor cocktail, resuspending in SDS loading buffer
with 9% 2-mercaptoethanol, boiling for 5 min, and separating by
PAGE as described (29). Proteins were transferred to nitrocellu-
lose (Schleicher & Schuell, Inc., Keene, NH) for Western blot-
ting or tryptic mapping experiments, or to polyvinylidene difluo-
ride (PVDF; Dupont-NEN, Boston, MA) for phosphoamino acid
analysis, and either exposed for autoradiography or subjected to
Western blot analysis as indicated (30). The anti–bcl-2 mouse
monoclonal antibody 4D7 (PharMingen, San Diego, CA) was
used for blotting studies at a dilution of 1:1,000. Nitrocellulose
blots were blocked with 5% Blotto (Bio-Rad Laboratories, Her-
cules, CA) in PBS overnight at 4
 
8
 
C. Bands were visualized using
RAM conjugated to horseradish peroxidase (Amersham Corp., Ar-
lington Heights, IL) at a dilution of 1:7,500 in 5% Blotto in PBS,
and developed using ECL chemiluminescence performed accord-
ing to the manufacturer’s instructions (Amersham Corp.).
 
Phosphoamino Acid Analysis.
 
Immunoprecipitates that had been
electrophoresed and transferred to PVDF were rinsed thoroughly
with water, exposed for radiography, and then appropriate bands
were excised with a razor blade. The radiolabeled bands were
then subjected to acid hydrolysis as described (31).
 
RNA Isolation and Identification.
 
Immunoprecipitates from
 
 
 
32
 
P-
labeled Jurkat cells were prepared as described above. After the
third NP-40 lysis buffer wash, the immunoprecipitate was di-
gested in a volume of 300 
 
m
 
l for 1 h at 37
 
8
 
C in a solution con-
taining 50 
 
m
 
g/ml proteinase K (Sigma Chemical Co.), 10 mM
Tris, pH 7.8, 10 mM EDTA, and 0.5% SDS. The RNA was iso-
lated after two extractions with a phenol/chloroform/isoamyl al-
cohol (25:24:1) mixture (GIBCO BRL). The RNA was precipi-
tated overnight at 
 
2
 
70
 
8
 
C after the addition of 20 
 
m
 
l 3 M sodium
acetate, 400 
 
m
 
l ethanol, and 10 
 
m
 
g transfer RNA (Sigma Chemi-
cal Co.) as a carrier. The pellet was obtained after a 15-min cen-
trifugation in an Eppendorf centrifuge maintained at 4
 
8
 
C. The
pellet was washed once with 70% ethanol, dried in a fume hood,
and subjected to PAGE on 6% sequencing gels. A small amount
of whole cell lysate was also processed as above and included as an
internal standard on each gel. 
 
Two-Dimensional Phosphopeptide Analysis.
 
Two-dimensional tryp-
tic phosphopeptide mapping was performed as described (32) us-
ing trypsin (Worthington Biochemical Corp., Freehold, NJ) at a
concentration of 0.1 mg/ml in 50 mM ammonium bicarbonate.
Plates were exposed to film at 
 
2
 
70
 
8
 
C with an intensifying screen
for 2 d.
 
Results
 
Autoimmune Sera Precipitate Phosphoproteins from Lysates
Prepared from Jurkat T Cells Undergoing Fas-induced Apopto-
sis.
 
Sera reactive with known autoantigens were first
tested for their ability to precipitate the expected protein or
complex from extracts prepared from 
 
35
 
S-labeled Jurkat
cells, as detected by SDS-PAGE followed by autoradio-
graphic exposure. Sera that precipitated ambiguous patterns
of proteins were subjected to further analysis by Western
blotting of both whole cell Jurkat extracts and immunopre-
cipitates prepared as above, to confirm that the well-char-
acterized sera precipitated the expected target antigen. Most
of the sera were derived from patients with autoimmune
disease. In addition, six murine monoclonal antibodies re-
active with known autoantigens (Ku, DNA-PK, lamins A
and B, Ki67, and PCNA) were included in this screen.
Jurkat cells metabolically labeled with 
 
32
 
P-orthophos-
phate were cultured for 3 h in the absence or presence of a
monoclonal antibody reactive with Fas (anti-7C11), solubi-
lized in NP-40 lysis buffer, and immunoprecipitated using
patient serum or monoclonal antibodies as previously de- 
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scribed (19). Immunoprecipitates were separated on a 12%
SDS–polyacrylamide gel, transferred to nitrocellulose, and
then subjected to autoradiography. Most sera did not pre-
cipitate unique phosphoproteins from apoptotic lysates. For
example, sera reactive with nuclear proteins implicated in
DNA replication, binding, or repair (i.e., Ku, DNA-PK,
PCNA, Scl-70, and histone) failed to reproducibly precipi-
tate new phosphoproteins from apoptotic Jurkat cell ex-
tracts (data not shown). Similarly, proteins present in the
nuclear matrix or involved in mitosis (i.e., lamins A and B,
centromere A and B, Ki-67, NuMA, sp140, and sp100),
the nucleolus (i.e., Th/To, UBF/NOR-90, RNA poly-
merase I, II, and III, and U3–snRNPs), or cytoplasmic
components of the translational apparatus (i.e., Jo-1, Pl-7,
Pl-12, SRP, and ribosomal P) were unmodified in these
experiments (data not shown). In contrast, several sera spe-
cific for U–snRNP
 
 
 
complexes precipitated phosphopro-
teins of 54, 42, 34, and 23 kD from apoptotic Jurkat cell
extracts (Fig. 1 
 
A
 
). The phosphorylation of these proteins
did not result from a nonspecific, general increase in kinase
activity after Fas engagement, as 
 
32
 
P-labeled, whole cell ex-
tracts prepared from untreated and apoptotic cells were
identical when analyzed by SDS PAGE (data not shown).
Moreover, this pattern was similar to that observed using
four distinct sera described in our previous report, suggest-
ing that these four proteins (termed pp54, pp42, pp34, and
pp23) may be previously unrecognized components of
U–snRNP complexes (19). As reported previously (19),
the constitutive phosphorylation of La (Fig. 1 
 
A
 
, 
 
Ro
 
 and
 
La
 
) was unaltered in cells undergoing apoptosis.
 
Autoimmune Sera Coprecipitate U–snRNP Proteins.
 
Immu-
noprecipitates were prepared from 
 
35
 
S-labeled lysates pre-
pared before (
 
2
 
) or 3 h after (
 
1
 
) Fas ligation (Fig. 1 
 
B
 
). Al-
though immunoprecipitates prepared from apoptotic and
nonapoptotic lysates contained 
 
35
 
S-labeled proteins migrat-
ing similarly to the phosphoproteins identified in Fig. 1 
 
A
 
,
we were unable to establish the relationship between the
 
32
 
P- and 
 
35
 
S-labeled proteins. Nevertheless, we did not ob-
serve the appearance of new 
 
35
 
S-labeled proteins corre-
sponding to components of the phosphoprotein complex.
Moreover, all five sera precipitated U–snRNP components
(e.g., the A, B, B
 
9
 
, and C proteins, indicated by arrows)
from labeled Jurkat cell extracts (Figs. 1 
 
B
 
 and 2, also see
below). Six other sera from patients with SLE and MCTD
possessing high titers of antibodies against Sm or RNP
components (as determined by ELISA assay), also precipi-
tated U–snRNP components from 
 
35
 
S-labeled Jurkat cell
extracts, as well as all four phosphoproteins from apoptotic
cell extracts prepared from 
 
32
 
P-labeled Jurkat cells (data not
shown). These results demonstrate that autoimmune sera
capable of precipitating U–snRNP proteins coprecipitate a
phosphoprotein complex containing pp54, pp42, pp34,
and pp23 from apoptotic Jurkat cell lysates.
 
Autoimmune Sera Coprecipitate the U1–snRNA Molecule
and pp54, pp42, pp34, and pp23.
 
To further establish that
pp54, pp42, pp34, and pp23 are components of U–snRNP
complexes, we used all five sera shown in Fig. 1 
 
B
 
, four
sera previously reported to precipitate these four phospho-
proteins (patients 1, 8, 11, and 12; reference 19), and con-
trol sera to identify the RNA molecules present in individ-
Figure 1. Human autoimmune sera specific for U–snRNP complexes precipitate phosphoproteins from apoptotic Jurkat cell lysates. (A) Jurkat cells
were labeled with 32P orthophosphate and lysed either before (2) or 3 h after (1) the addition of anti-Fas 7C11. Proteins were then precipitated using
the indicated autoimmune serum, separated on a 12% SDS–polyacrylamide gel, transferred to nitrocellulose, and exposed for autoradiography. Individual
sera are described in detail in Materials and Methods. U-serum 1, Immunovision antihistone/RNP; U-serum 2, CDC/AF reference serum 4 (anti-U1–RNP);
U-serum 3, serum Ga; U-serum 4, serum Ya; U-serum 5, CDC/AF reference serum 5 (anti-Sm). The relative migration of molecular mass markers in kilo-
daltons is indicated on the left side of the gel. (B) Immunoprecipitation from 35S-labeled Jurkat cells. Jurkat cells were labeled with 35S-methionine and
cysteine and lysed either before (2) or 3 h after (1) the addition of anti-Fas 7C11 before immunoprecipitation using sera derived from the indicated pa-
tient. Immunoprecipitates were separated on a 12% SDS–polyacrylamide gel, transferred to nitrocellulose, and then subjected to autoradiographic analy-
sis. The relative migration of molecular mass markers in kilodaltons is indicated on the left side of each panel. Bands corresponding to the U–snRNP proteins
A, B, B9, and C are indicated on the right side of the panel. 
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ual immunoprecipitates. Jurkat cells metabolically labeled
with 
 
32P-orthophosphate were solubilized in NP-40 lysis
buffer, RNA was extracted from washed immunoprecipi-
tates, separated on a 6% polyacrylamide gel, and subjected
to autoradiography. As shown in Fig. 2, all sera capable of
precipitating the phosphoprotein complex also precipitate
the U1–snRNA. A similar result was obtained for another
well-characterized serum previously shown to recognize
the U1-70 kD protein (Fig. 2, lane 6, U-serum 6, a gift of
A. Rosen; reference 10). We noted that one sample (U-serum
2, Fig. 2, lane 10) specifically precipitated the U1– but not
the U2–snRNA molecule, suggesting that pp54, pp42, pp34,
and pp23 may be components of the U1–snRNP complex.
To confirm this observation, we screened seven additional
human sera previously shown to specifically precipitate the
U1–snRNP complex (91), and serum V26 (which precipi-
tates both the U1– and U2–snRNPs; reference 23) for
their ability to coprecipitate pp54, pp42, pp34, and pp23
from 32P-labeled, apoptotic Jurkat cell extracts. All 7 sera
coprecipitated the U1–snRNA (Fig. 3 A) and all four
phosphoproteins (Fig. 3 B). Identical results were obtained
using serum V26 (data not shown). Interestingly, individual
sera precipitated phosphoproteins of varying intensity (e.g.,
all four phosphoproteins are precipitated by serum B83,
Fig. 3 B, lane 2, but mainly pp42 and pp54 are precipitated
by serum H165, Fig. 2, lane 10). This may result from het-
erogenous populations of antibodies directed against indi-
vidual U1–snRNP components, or by antibodies that rec-
ognize the phosphoprotein directly. None of the control
antibodies directed against Ro, La, ribosomal P, or SRP
Figure 2. Coprecipitation of U1–snRNA using selected autoantisera.
Jurkat cells were labeled with 32P-orthophosphate and solubilized in NP-
40 lysis buffer. After immunoprecipitation with the indicated serum,
RNA was extracted and separated on 6% sequencing gels before drying
and autoradiographic exposure. The relative migration of known RNA
moieties is depicted on the right side of the figure. The serum specificity
is indicated above each sample. Lanes are numbered at the bottom of the
panel. Lanes 1–4, patients 1, 8, 11, 12 (19); U-serum 1, Immunovision an-
tihistone/RNP; U-serum 2, CDC/AF reference serum 4 (anti-U1–RNP);
U-serum 3, serum Ga; U-serum 4, serum Ya; U-serum 5, CDC/AF refer-
ence serum 5 (anti-Sm); U-serum 6, anti–U1-70 kD serum (gift of A.
Rosen).
Figure 3. U1-specific autoantisera coprecipitate the U1–snRNA mole-
cule and pp54, pp42, pp34, and pp23 from apoptotic extracts. (A) Jurkat
cells were labeled with 32P-orthophosphate and lysed in NP-40 lysis
buffer. After immunoprecipitation with the indicated serum, RNA was
extracted and separated on 6% sequencing gels before drying and autora-
diographic exposure. Patient sera specific for the U1–snRNP complex
were used in lanes 1–7. A patient serum (V26, lane 8) capable of precipi-
tating both the U1– and U2–snRNPs is shown for comparison. The rela-
tive migration of the U1– and U2–snRNAs is depicted on the right side
of the figure. (B) Jurkat cells were labeled with 32P-orthophosphate and
lysed either before (2) or 3 h after (1) the addition of anti-Fas (7C11)
before immunoprecipitation using sera derived from the indicated patient.
Immunoprecipitates were separated on a 12% SDS–polyacrylamide gel,
transferred to nitrocellulose, and subjected to autoradiographic analysis.
Sera correspond to the seven U1-specific autoantisera shown in Fig. 3 A.
The relative migration of molecular size markers in kilodaltons is indi-
cated on the left side of the figure. Bands corresponding to pp54, pp42,
pp34, and pp23 are shown on the right side of the panel. A high molecu-
lar mass complex is indicated with a large arrowhead. Lanes are numbered
at the bottom of the figure.552 Serine/Arginine Splicing Factors in Apoptosis
precipitated either the U–snRNAs or any of the four phos-
phoproteins (data not shown). Several sera also precipitated
phosphoproteins between 96 and 200 kD that were no
longer detected after Fas stimulation (e.g., B152, H34, and
K4, Fig. 3 B, lanes 3, 7, and 11), again suggesting that these
sera likely recognize heterogeneous epitopes of the U1–
snRNP particle. It is unknown if this represents dephosphory-
lation, caspase cleavage, or dissociation of these phospho-
proteins from the immunoprecipitate after the apoptotic
stimulus. These results suggest that the U1–snRNP is a dy-
namic particle that is altered by caspases (U1-70 kD pro-
tein; reference 10), and potentially by kinases (pp54, pp42,
pp34, and pp23; reference 19) and phosphatases (the high
molecular mass protein complex shown in Fig. 3 B) during
apoptosis.
Monoclonal Antibodies Directed Against U1–snRNP Compo-
nents Precipitate pp54, pp42, pp34, and pp23 from Apoptotic Jurkat
Cell Lysates. To confirm our results described above us-
ing human autoimmune serum, and to determine whether
pp54, pp42, pp34, and pp23 exist in both the U1– and
U2–snRNP splicing complexes, we used a series of mono-
clonal antibodies directed against proteins common or
unique to each U–snRNP complex. Specifically, we tested
antibodies directed against the U1-70 kD component of
the U1–snRNP, the U2B99 protein of the U2–snRNP
(4G3), the anti-Sm monoclonal antibody Y12, and a mono-
Figure 4. Monoclonal antibodies directed against
U1–snRNP components precipitate pp54, pp42,
pp34, and pp23 from extracts prepared from apop-
totic Jurkat cells. (A) Jurkat cells were labeled with
32P-orthophosphate and lysed either before (2) or 3 h
after (1) the addition of anti-Fas 7C11. Proteins
were then precipitated using the indicated autoim-
mune serum, separated on a 12% SDS–polyacryl-
amide gel, transferred to nitrocellulose, and then ex-
posed for autoradiography. The relative migration of
molecular mass markers in kilodaltons is indicated on
the left side of the gel. Bands corresponding to pp90,
pp54, pp42, pp34, and pp23 are shown on the right
side of the panel. Lanes are numbered at the bottom
of the panel. (B) The identical experiment in 35S-labeled
Jurkat cells. The relative migration of molecular size
markers in kilodaltons is indicated on the left side of
the gel. Lanes are numbered at the bottom of the
figure. (C) Phosphoamino acid analysis of pp54,
pp42, pp34, and pp23. Jurkat cells were labeled with
32P-orthophosphate, treated with the anti-Fas mono-
clonal antibody 7C11, and solubilized using NP-40
lysis buffer after 3 h. Proteins were then precipitated with the anti-U1A/U2B99 monoclonal antibody 9A9, separated on a 12% SDS–polyacrylamide gel,
transferred to PVDF, and exposed for autoradiography. Individual phosphoproteins were localized on the membrane, excised, and then subjected to acid
hydrolysis. Phosphoamino acids were separated by two-dimensional electrophoresis in pH 1.9 buffer in the horizontal dimension, followed by pH 3.5
buffer in the vertical dimension before autoradiographic analysis. Individual proteins are labeled on the side of each panel. Migration of phosphoamino
acid standards are labeled with circles as follows: phosphoserine (pS), phosphothreonine (pT), phosphotyrosine (pY). (D) Anti-U1A antibody fragments
coprecipitate pp54, pp42, pp34, and pp23 from apoptotic Jurkat cell lysates. Labeled Jurkat cell extracts were prepared as above. Proteins were precipi-
tated using the indicated anti-U1A antibody fragments, separated on a 12% SDS–polyacrylamide gel, transferred to nitrocellulose, and then exposed for
autoradiography. The relative migration of molecular mass markers in kilodaltons is indicated on the right side of the gel. Bands corresponding to pp54,
pp42, pp34, and pp23 are shown on the left side of the panel.553 Utz et al.
clonal antibody (9A9) that recognizes an epitope common
to both U1A and U2B99 for their ability to precipitate
pp54, pp42, pp34, and pp23 from apoptotic extracts. Jurkat
cells metabolically labeled with 32P-orthophosphate were
cultured for 3 h in the absence or presence of a monoclonal
antibody reactive with Fas (anti-7C11), solubilized in NP-40
lysis buffer, and individually immunoprecipitated using each
of these antibodies; control antibodies directed against
other RNA-binding proteins included monoclonal anti-
bodies against Ro60, Ro52, La, and the anti-T cell intra-
cellular antigen-related protein (TIAR) antibody 6E3 (33).
As shown in Fig. 4 A, the Smith antibody Y12, and the
9A9 monoclonal antibody specific for the U1A and U2B99
proteins (both of which recognize components common to
both U1– and U2–snRNPs) precipitate all four phospho-
proteins from apoptotic Jurkat cell lysates (Fig. 4, A and B,
lanes 2 and 8). These bands are absent in the lanes corre-
sponding to the immunoprecipitation using anti-U2B99
(Fig. 4, A and B, lane 6) and anti–U1-70 kD monoclonal
antibodies (A and B, lane 4, see Discussion). Interestingly,
increased phosphorylation of a 90-kD protein is observed
after Fas stimulation when immunoprecipitates are pre-
pared using anti-U2B99 (4G3) antibody (Fig. 4, A and B,
lane 6), and on a short exposure of the lanes corresponding
to the U1A/U2B99 immunoprecipitate (Fig. 4, A and B,
lanes  7 and 8, data not shown), suggesting that a specific phos-
phoprotein (henceforth called pp90) is associated with the
U2–snRNP during apoptosis. Bands corresponding to
pp90, pp54, pp42, pp34, and pp23 are absent using mono-
clonal antibodies directed against TIAR (6E3, Fig. 4, A and
B, lane 10), Ro60 (lane 12), Ro52 (lane 14), La (lane 16),
or the putative apoptosis effector TIA-1 (data not shown),
another autoantigen that is known to be reversibly phos-
phorylated during Fas-mediated apoptosis, but at an earlier
time point (19, 34, 35). The same experiment performed in
cells labeled with [35S]methionine and cysteine (Fig. 4 B)
demonstrates no difference between immunoprecipitates
prepared from apoptotic and nonapoptotic cell extracts,
consistent with the results shown in Fig. 1 B. Phospho-
amino acid analysis of all four proteins precipitated using
anti-U1A/U2B99 (9A9) demonstrates exclusive phosphory-
lation of pp54, pp42, pp34, and pp23 on serine residues
(Fig. 4 C).
The failure of the U1-70 kD monoclonal antibody to
precipitate pp54, pp42, pp34, and pp23 from apoptotic ly-
sates appeared to be inconsistent with the hypothesis that
these phosphoproteins are specifically associated with the
U1–snRNP during apoptosis. To address this apparent par-
adox (see Discussion), we used two previously described
human variable domain antibody fragments directed against
a different, unique component of the U1–snRNP (the U1A
protein) and repeated the immunoprecipitation experi-
ments (21). Both antibodies (Fig. 4 D, lanes 1–4) coprecip-
itate a phosphoprotein complex containing pp54, pp42,
pp34, and pp23, but not pp90. A control antibody frag-
ment directed against bovine serum albumin precipitates
only a faint, nonspecific 60-kD protein (Fig. 4 D, lanes 5
and 6). Taken together, these results demonstrate an associ-
ation between a phosphoprotein complex (containing pp54,
pp42, pp34, and pp23) and the U1–snRNP during apopto-
sis and suggests that pp90 may be associated specifically
with the U2–snRNP during apoptosis.
Association of pp54, pp42, pp34, and pp23 with U–snRNPs
Accompanies Apoptosis but Not T Cell Receptor Stimulation.
Previously, we had demonstrated that, in addition to death
induced by Fas ligation, phosphorylated autoantigens are
also immunoprecipitated during apoptosis triggered by
other stimuli including gamma and UV irradiation, but not
by T cell receptor stimulation (19). We repeated this ex-
periment using the anti-U1A/U2B99 (9A9) monoclonal an-
tibody in immunoprecipitation experiments using 32P-labeled
Jurkat lysates prepared from cells subjected to apoptotic
stimuli or an activation stimulus over a 5-h time course
(Fig. 5). This analysis reveals that phosphorylated autoanti-
gens are precipitated beginning at the 3-h time point after
Fas cross-linking (Fig. 5, lanes 1–4) or UV irradiation (Fig.
5, lanes 11–14), and much less intense bands are observed
5 h after gamma irradiation (Fig. 5, lanes 5–7), consistent
with our initial observations (19). In contrast, ligation of
the T cell receptor complex using a monoclonal antibody
reactive with CD3, a stimulus that induces IL-2 production
and enhances proliferation in these cells (data not shown),
induced neither precipitation of phosphoproteins (Fig. 5,
lanes 8–10) nor DNA fragmentation (data not shown and
reference 19) over the course of this experiment.
Bcl-2 Overexpression Blocks Gamma Irradiation–induced
Apoptosis and Precipitation of pp54, pp42, pp34, and pp23.
Next, we asked whether the precipitation of these phos-
Figure 5. Phosphoprotein components of the U1–snRNP complex are
precipitated after multiple apoptotic stimuli but not an activation stimulus.
Jurkat cells were labeled with 32P-orthophosphate, treated with the in-
dicated stimulus, and then solubilized using NP-40 lysis buffer at the indi-
cated times. Proteins were then precipitated with anti-U1A/U2B99, sepa-
rated on a 12% SDS–polyacrylamide gel, transferred to nitrocellulose, and
then exposed for autoradiography. The apoptotic stimulus is indicated
above each panel. The time in hours after each stimulus is indicated above
each lane. The relative migration of molecular mass markers in kilodaltons
is indicated on the left side of the panel. Bands corresponding to pp54,
pp42, pp34, and pp23 are shown on the right side of the panel. Lanes are
numbered at the bottom of each panel.554 Serine/Arginine Splicing Factors in Apoptosis
phorylated U1–snRNP components could be blocked by
overexpression of the bcl-2 protein, which has been shown
to efficiently block apoptosis induced by multiple apoptotic
stimuli, including gamma irradiation and UV irradiation
(19, 36–39). As shown in Fig. 6, Jurkat T cells stably trans-
formed with either bcl-2 (lanes 1–4) or empty vector (lanes
5–8) were labeled with 32P-orthophosphate and subjected
to gamma irradiation. Cells were solubilized at the indi-
cated times and lysates were precipitated using the anti-
U1A/U2B99 (9A9) monoclonal antibody. Whereas precip-
itation of phosphorylated pp54, pp42, pp34, and pp23 is
rapidly induced in Jurkat (neo) control cells in response to
gamma irradiation (Fig. 6, lanes 5–8), the intensity of the
bands corresponding to the four phosphoproteins is un-
changed in Jurkat (bcl-2) transformants treated with this
same stimulus (Fig. 6, lanes 1–4). Short exposure of the gel
in Fig. 6 showed that bcl-2 overexpression also inhibited
the appearance of pp90 (data not shown). Ectopic expres-
sion of bcl-2 effectively inhibited apoptosis in response to
gamma irradiation, as judged by the induction of DNA
fragmentation (data not shown and reference 19). Taken
together, these results demonstrate that the coprecipitation
of all five phosphorylated snRNP factors correlates with
the induction of apoptosis and is downstream of the inhibi-
tory effects of bcl-2.
Monoclonal Antibodies Specific for SR Splicing Factors Precipi-
tate a Phosphoprotein Complex Containing pp54, pp42, pp34,
and pp23 from Apoptotic Jurkat Cell Lysates. The identifica-
tion of pp54, pp42, pp34, and pp23 as components of the
U1–snRNP complex prompted us to search for known
phosphoprotein components of these splicing particles. Re-
view of the literature identified the SR family of splicing
factors as excellent candidates. Five of the most abundant
SR proteins are virtually identical in molecular mass to pp54,
pp42, pp34, and pp23 (i.e., SRp55, SRp40, SC35, ASF/
SF-2, and SRp20) and are phosphorylated on serine resi-
dues in vivo and in vitro (40). To test the possibility that
pp54, pp42, pp34, and pp23 might be SR proteins, the ex-
periment shown in Fig. 7 was performed. Jurkat cells meta-
bolically labeled with 32P-orthophosphate were cultured for
3 h in the absence (2) or presence (1) of a monoclonal an-
tibody reactive with Fas (anti-7C11), solubilized in NP-40
lysis buffer, and then immunoprecipitated using 9A9 (anti-
U1A/U2B99), mAb104 (a monoclonal antibody specific for
the phospho-SR domain of these factors; reference 28), or
anti-SC35 (a monoclonal antibody specific for the phos-
phorylated form of SC35). Labeled proteins were separated
by SDS PAGE and transferred to nitrocellulose. Fig. 7 A
demonstrates that both mAb104 and anti-SC35 coprecipi-
tate the same phosphoprotein complex from apoptotic ly-
sates. To confirm that the respective proteins precipitated
with each antibody are identical, bands corresponding to
pp54, pp42, pp34, and pp23 (from immunoprecipitates
prepared independently using anti-SC35 and 9A9, Fig. 7 A,
lanes 2 and 4) were localized by autoradiography, excised,
and then subjected to two-dimensional phosphotryptic
mapping. As shown for one of the bands (pp34), the phos-
photryptic maps are identical (Fig. 7 B). Similar results were
obtained when comparing phosphopeptide maps corre-
sponding to pp54, pp42, and pp23 (data not shown).
Taken together, these results demonstrate that a phospho-
protein complex is selectively associated with the U1–snRNP
complex during apoptosis, and identify members of the SR
family of splicing factors as likely components of this phos-
phoprotein complex.
Discussion
Autoimmune sera have been used extensively as probes
to identify, characterize, and clone proteins and RNA mol-
ecules with important cellular functions. Proteins such as
La and the U1-70 kD component of the U1–snRNP com-
plex were cloned using serum from SLE patients to screen a
phage expression library (41, 42), and antibodies directed
against Sm proteins and the Th/To antigen have been used
to identify their function in vitro by inhibiting specific
steps in mRNA and nucleolar RNA processing, respec-
tively (43, 44). More recently, serum from such patients has
proven useful for the identification of proteins that are
cleaved by caspases during apoptosis. We have used a simi-
lar strategy to identify proteins that may be phosphorylated
during stress-induced apoptosis (19). Before our recent re-
port (18), only a few such proteins had been identified, and
several of these proteins have been implicated as critical ef-
fectors of cell death. The TIA-1 autoantigen (Utz, P.J., and
P. Anderson, unpublished data) is phosphorylated by Fas-
Figure 6. In vivo phosphorylation of U1–snRNP components is inhib-
ited in gamma-irradiated Jurkat cells overexpressing bcl-2. Jurkat (bcl-2) trans-
formants (lanes 1–4) or Jurkat (neo) control transformants (lanes 5–8) were
labeled with 32P-orthophosphate, subjected to gamma irradiation, solubi-
lized in NP-40 lysis buffer, precipitated using anti-U1A/U2B99 antibod-
ies, separated on a 12% SDS–polyacrylamide gel, transferred to nitrocellu-
lose, and then exposed for autoradiography. The relative migration of
molecular size markers in kilodaltons is indicated on the left side of the
figure. Bands corresponding to pp54, pp42, pp34, and pp23 are shown on
the right side of the figure. The time, in hours, from initial exposure to
gamma irradiation is indicated at the top of each lane. Lane numbers ap-
pear at the bottom of the figure.555 Utz et al.
activated serine/threonine kinase (FAST kinase) during ap-
optosis (35), and it is postulated that TIA-1 and a related pro-
tein, TIAR, differentially regulate RNA metabolism in re-
sponse to apoptotic stimuli (Anderson, P., and N. Kedersha,
unpublished observations; reference 34). Another kinase
(termed JNK) phosphorylates and activates the c-jun tran-
scription factor in response to multiple apoptotic stimuli
(45–48). Overexpression of an NH2-terminal deletion mu-
tant of the c-jun protein acts as a dominant negative sup-
pressor of apoptosis. Recent reports, however, suggest that
kinases such as JNK are activated after both lethal and non-
lethal stimuli, and thus may be dispensable for execution of
the apoptotic program under some circumstances (49, 50).
The U–snRNPs are a group of related nuclear particles
containing a unique, uridine-rich, structural RNA (termed
the U–snRNA) and a core of six or more polypeptides
(51). The most abundant of these, the U1–, U2–, U5–, and
U4/U6–snRNP complexes are known autoantigens (22,
51–54) and play critical roles in the splicing of pre-mRNA
molecules. During splicing, U–snRNPs assemble into a
macromolecular structure termed a “spliceosome” whose
function is to efficiently and precisely process introns from
pre-mRNA before export of the mature mRNA from the
nucleus. The fidelity of this complex process is facilitated
by other splicing factors that transiently associate with the
U–snRNP complexes, particularly the U1– and U2–snRNPs
(55, 56). Splicing factors belonging to the SR family are
highly conserved proteins containing one or more RNA
recognition motifs (RRMs) at their NH2 termini and a SR
repeat of varying length in their COOH termini (57).
Structural analysis of the SR protein ASF/SF2 demon-
strates that the SR domains are required for protein phos-
phorylation and constitutive RNA splicing but are dispens-
able for alternative splicing. Targeted disruption of the
RRM domains blocks RNA binding and constitutive
splicing activity (58, 59). At least eight proteins containing
SR domains have been identified in humans, including the
U1-70 kD protein, SRp75, SRp54, SRp40, ASF/SF2,
SC35, U2AF35, and SRp20. Six of these eight proteins
(SRp54, SRp40, ASF/SF2, SC35, U2AF35, and SRp20)
are similar in size to the proteins described above (pp54,
pp42, pp34, and pp23). It has been postulated that SR proteins
enhance splicing by binding to the U1–snRNP during the
formation of a commitment complex, thus stabilizing the spli-
ceosome assembly (60–62). Individual SR proteins can substi-
tute for the U1–snRNP in in vitro splicing assays (63), and SR
proteins have been implicated in regulation of both consti-
tutive and alternative splicing of several mRNAs (57, 64–69).
Reversible protein phosphorylation is thought to regu-
late both constitutive and alternative mRNA splicing. Ex-
periments using phosphatase inhibitors, nonhydrolyzable ATP
analogues, or purified phosphatases in in vitro splicing re-
actions demonstrates a requirement for reversible protein
phosphorylation for mRNA splicing (70–72), and several
kinases capable of phosphorylating SR proteins have been
identified. The U1-70 kD snRNP protein is an in vivo
and in vitro substrate for an unidentified serine kinase that
copurifies with the U1–snRNP complex (73). A second
kinase, SR protein kinase-1 (SRPK-1), capable of phos-
phorylating multiple different SR proteins has also been
identified (40, 74–76). Interestingly, this kinase is active
during mitosis, phosphorylates substrates exclusively on se-
rine residues, copurifies with snRNP complexes, and dis-
rupts both nuclear speckles and in vitro pre-mRNA splic-
ing (40). All five of the known in vitro substrates for
SRPK-1 are identical in size to the proteins described in
this report and include SRp55 (pp54), SRp40 (pp40), SC35
(pp34), ASF/SF2 (pp34), and SRp20 (pp23; references 19,
40). A related kinase, Clk/Sty, has also been shown to
phosphorylate SR proteins in vitro (76, 77). Despite these
Figure 7. Monoclonal antibodies specific
for SR proteins precipitate pp54, pp42,
pp34, and pp23 from apoptotic Jurkat cell
extracts. (A) Jurkat cells were labeled with
32P-orthophosphate and lysed either before
(2) or 3 h after (1) the addition of anti-Fas
7C11. Proteins were then precipitated using
the indicated monoclonal antibody, sepa-
rated on a 12% SDS–polyacrylamide gel,
transferred to nitrocellulose, and exposed
for autoradiography. The relative migration
of pp34 is indicated on the left side of the
gel. Lanes are numbered at the bottom of
the panel. The relative migration of molec-
ular size markers in kilodaltons is indicated
on the right side of the figure. (B) Two-
dimensional phosphotryptic map of pp34.
The 34-kD band from the U1A/U2B99 im-
munoprecipitate (lane 2) and the anti-SC35
immunoprecipitate (lane 4) were excised
and digested with trypsin. Phosphopeptides
were separated electrophoretically at pH 1.9
in the first dimension, and by thin-layer
chromatography in the second dimension
before autoradiographic exposure. Direction
of separation is shown by arrows. E, elec-
trophoresis; C, chromatography; O, origin.556 Serine/Arginine Splicing Factors in Apoptosis
intriguing reports, to date there have been no studies di-
rectly linking a serine kinase to the phosphorylation of
splicing factors during stress-induced apoptosis. Experi-
ments designed to identify whether SRPK-1, Clk/Sty, the
U1-70 kD kinase or a novel serine kinase is responsible for
the apoptosis-specific phosphorylation of SR proteins, and
the role that this modification plays in apoptosis and alter-
native mRNA splicing, are in progress.
The evidence suggesting that pp54, pp42, pp34, and pp23
are components of the U1–snRNP is compelling. First, all
4 autoimmune sera from our initial report (19) and 20 sera
described herein simultaneously precipitate all 4 phospho-
proteins (Figs. 1 and 3 B) together with the U1 RNA (Figs.
2 and 3 A), from lysates prepared from Fas-treated Jurkat
cells. Second, two different monoclonal antibodies (Y12
and 9A9) that recognize core (Sm) components of the U1–
snRNP complex also precipitate these same four phospho-
proteins from extracts prepared from apoptotic Jurkat cells,
whereas monoclonal antibodies directed against six other
RNA-binding proteins do not (Fig. 4). Third, two human
variable domain antibody fragments directed against over-
lapping epitopes of the U1A protein coprecipitate pp54,
pp42, pp34, and pp23 from apoptotic Jurkat cell extracts
(Fig. 4 D). Finally, the anti-U1A/U2B99 (9A9) monoclonal
antibody precipitates all four phosphoproteins from extracts
prepared from cells subjected to multiple different apop-
totic stimuli but not after engagement of the T cell recep-
tor, and the association of these phosphoproteins with the
U–snRNPs is blocked in cells engineered to overexpress
bcl-2 (Figs. 5 and 6). Thus, all of the experiments described
using SLE sera from our initial report have been replicated
using the anti-U1A/U2B99 (9A9) monoclonal antibody (19).
It remains to be determined whether phosphoproteins
are also associated with the U2– and other U–snRNP com-
plexes during apoptosis. Two human sera and four mono-
clonal antibodies specific for components of the U3–snRNP
complex failed to coprecipitate pp54, pp42, pp34, or pp23
(data not shown). A monoclonal antibody directed against
the U2B99 protein that uniquely precipitated the U2–snRNA
(data not shown) was incapable of precipitating pp54,
pp42, pp34, and pp23 in most (.10) experiments. Rarely,
faint bands migrating at 54, 42, 34, and 23 kD were ob-
served on long exposures (data not shown). While this may
represent the direct association of the U2–snRNP and the
SR proteins, it is equally plausible that these bands repre-
sent the association of SR proteins, U1– and U2–snRNPs
in an active spliceosome complex.
The identification of pp54, pp42, pp34, and pp23 as SR
proteins is suggested by several observations. The respec-
tive SR proteins SRp54, SRp42, SC35, ASF/SF2, and
SRp20 have similar migration patterns on SDS PAGE and
are phosphorylated exclusively on serine residues (74). SR
proteins also interact with components of the spliceosome
and copurify with the U1–snRNA during gel filtration anal-
ysis (78, 79) and sucrose gradient centrifugation (our un-
published data). All four proteins (pp54, pp42, pp34, and
pp23) comigrate with their respective SR counterparts dur-
ing two-dimensional gel electrophoresis, and anti-SC35 is
capable of coprecipitating the U1–snRNA (data not shown).
Finally, an identical phosphoprotein complex is precipi-
tated by two monoclonal antibodies specific for the phos-
phorylated forms of SR proteins (Fig. 7; reference 28, 80).
A much more difficult question is whether these proteins
are stable components of the U1–snRNP that are phosphor-
ylated de novo after an apoptotic stimulus, or rather are re-
cruited to the U1–snRNP complex during apoptosis. SR
proteins have few methionine and cysteine residues (two
SR proteins have no methionines other than the initiator),
perhaps explaining why bands corresponding to these pro-
teins are not consistently observed when immunoprecipi-
tates are prepared from 35S-labeled Jurkat cells. Although
the de novo phosphorylation model is favored by the iden-
tification of at least three kinases capable of phosphorylating
SR domain–containing proteins (40, 73–77), we cannot
exclude the possibility that a small fraction of the phosphor-
ylated forms of pp54, pp42, pp34, and pp23 (i.e., an amount
below the level of detection obtained by metabolic labeling
with [35S]methionine and cysteine) are recruited to the
U1–snRNP complex during apoptosis. The answer to this
important question awaits the development of other re-
agents, including anti-SR antibodies that recognize non-
phosphorylated SR proteins and epitope-tagged SR pro-
teins for use in transfection experiments.
The inability of the U1-70 kD monoclonal antibody to
coprecipitate pp54, pp42, pp34, and pp23 appeared to con-
tradict our argument that these phosphoproteins are associ-
ated with the U1–snRNP during apoptosis. This prompted
us to test monoclonal antibodies specific for other compo-
nents of the U1–snRNP for their ability to precipitate
this phosphoprotein complex (Fig. 4 D). We hypothesize
that only a subfraction of the U1–snRNP complexes
present in a cell is associated with SR proteins. In this
model, the U1A/U2B99 (9A9), anti-Sm (Y12), and anti-
U1A monoclonal antibodies recognize this population,
while the U1-70 kD monoclonal antibody recognizes a dif-
ferent population that is incapable of interacting with SR
proteins, perhaps by a steric hindrance. It is also possible
that caspase-mediated cleavage of U1-70 kD during apop-
tosis disrupts the interaction of U1-70 kD with other SR
proteins, an event that may explain the observation that
overexpression of the COOH terminus of U1-70 kD (which
contains tandem SR domains that are separated after
caspase cleavage; reference 81) acts as a dominant negative
suppressor of RNA splicing and RNA transport (82). Sev-
eral reports identifying a direct interaction between U1-70
kD and SR proteins support both possibilities (61, 62).
In addition to transcriptional and translational regulation
of apoptosis, our results suggest that a third regulatory
mechanism for programmed cell death is at the level of
messenger RNA splicing. It has been shown that cells ex-
pressing the larger splice variant of the bcl-x gene (bcl-xL)
are protected against cell death, while cells expressing the
short form lacking the highly conserved BH1 and BH2 in-
teraction domains (bcl-xS) have an increased susceptibility557 Utz et al.
to cell death (36, 83–85). Similar regulation has been de-
scribed for the Caenorhabditus elegans ced-4 gene product
(86), for the death domain-containing receptor LARD
(87), and for caspase 2 (Nedd2/Ich1) in which the protein
product of the larger splice variant (Ich1L) is proapoptotic
and the shorter variant (Ich1S) is protective (36, 83–85). It
has been shown that reversible phosphorylation of SR pro-
teins (e.g., ASF/SF2) can alter their ability to select alterna-
tive mRNA splice sites (65, 88, 89). It is tempting to spec-
ulate that SR protein phosphorylation may regulate levels
of prosurvival factors such as bcl-xL and Ich1S, or of proap-
optotic factors such as bcl-xS and Ich1L, thus altering the
susceptibility of a particular cell to an apoptotic trigger.
Although this is unlikely to be an important mechanism af-
ter engagement of a dedicated death receptor such as Fas or
the TNF receptor, both of which rapidly activate irrevers-
ible caspase cascades, alternative splicing of bcl-x, caspase 2,
and other unidentified mRNAs may be a critical check-
point when cells are subjected to slowly lethal or sublethal
stimuli.
Autoantibodies reactive with core components of the
U1–snRNP (anti-Sm) are specifically found in patients with
SLE. The observation that snRNP particles reside in plasma
membrane blebs formed at the surface of cells undergoing
apoptosis suggests that antigens presented in this manner
might bypass normal mechanisms of tolerance. In addition
to its subcellular localization, the U1–snRNP complex un-
dergoes profound structural alterations in cells undergoing
apoptosis. These structural alterations could produce novel
peptide epitopes to which T cells have not been rendered
tolerant. This may be particularly important for the pro-
duction of autoantibodies reactive with the U1–snRNP
complex, which is subject to the phenomenon of “epitope
spreading” whereby an immune response to one compo-
nent of the particle promotes the formation of antibodies
reactive with other components of the particle (90). We
propose that a T cell response directed against modified
components of the U1–snRNP complex (e.g., caspase-
cleaved U1-70 kD and/or phosphorylated SR-derived
peptides) may promote the formation of antibodies reactive
with other components of the complex. By driving the
maturation of potentially self reactive B cells specific for
components of the U1–snRNP particle, T cells recogniz-
ing these neoepitopes could be essential for autoantibody
production. It is currently unknown whether human au-
toantisera directly recognize SR proteins. With the identi-
fication of monoclonal antibodies capable of recognizing
pp54, pp42, pp34, and pp23 in apoptotic Jurkat cells, it
should now be possible to address these and several other
important questions. Are SR proteins stable components of
the U1–snRNP complex that are phosphorylated during
apoptosis, or are they recruited to the complex during cell
death? What is the kinase responsible for SR protein phos-
phorylation, and what is its role in programmed cell death
pathways and RNA splicing? Answers to these important
questions and the identification of other posttranslational
modifications of autoantigens during apoptosis are certain
to yield valuable clues to the pathogenic mechanisms un-
derlying autoimmune diseases such as SLE, scleroderma,
MCTD, and Sjögren’s Syndrome. Further studies may iden-
tify components of this putative kinase pathway as novel
molecular targets for pharmacologic therapy of autoim-
mune disease.
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